Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG

Journal of Surgical Research

Volumn 176, Issue 1, 2012, Pages 147-153

  Liu, Heping ^a   Zhang, Ti ^b   Chen, Rong ^a   McConkey, David J ^a   Ward, John F ^a   Curley, Steven A ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

17 AAG; chemosensitivity; kinase; pancreatic cancer

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; GLYCOPROTEIN P; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN P53; PROTEIN S6; SMALL INTERFERING RNA; SORAFENIB; TANESPIMYCIN;

ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; CHEMOSENSITIVITY; DRUG EFFECT; ENZYME INHIBITION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; MOLECULAR CLONING; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; BENZOQUINONES; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MUTATION; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PYRIDINES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84862001413     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2011.09.017     Document Type: Article

References (26)

1. P. Blume-Jensen, and T. Hunter Oncogenic kinase signaling Nature 411 2001 355
2. L. Whitesell, E.G. Mimnaugh, and B. De Costa Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation Proc Natl Acad Sci U S A 91 1994 8324
3. L. Sepp-Lorenzino, Z. Ma, and D.E. Lebwohl Herbimycin A induces the 20 S proteasome- and ubiquitin-dependent degradation of receptor tyrosine kinases J Biol Chem 270 1995 16580
4. E.G. Mimnaugh, C. Chavany, and L. Neckers Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin J Biol Chem 271 1996 22796
5. A. Kamal, M.F. Boehm, and F.J. Burrows Therapeutic and diagnostic implications of Hsp90 activation Trends Mol Med 10 2004 283
6. L. Neckers Using natural product inhibitors to validate Hsp90 as a molecular target in cancer Curr Top Med Chem 6 2006 1163
7. S. Modi, A.T. Stopeck, and M.S. Gordon Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: A phase I dose-escalation study J Clin Oncol 25 2007 5410
8. K.C. Anderson, A.L. Hannah, and R. Pazdur A strategic framework for novel drug development in multiple myeloma Br J Haematol 138 2007 153
9. D.B. Solit, I. Osman, and D. Polsky Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma Clin Cancer Res 14 2008 8302
10. J.A. Endicott, and V. Ling The biochemistry of P-glycoprotein-mediated multidrug resistance Annu Rev Biochem 58 1989 137
11. A.K. McCollum, C.J. TenEyck, and B. Stensgard P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response Cancer Res 68 2008 7419
12. M.N. Benchekroun, E. Schneider, and A.R. Safa Mechanisms of resistance to ansamycin antibiotics in human breast cancer cell lines Mol Pharmacol 46 1994 677
13. J.M. Lee, and A. Bernstein Apoptosis, cancer and the p53 tumor suppressor gene Cancer Metastasis Rev 14 1995 149
14. G.A. Lang, T. Iwakuma, and Y.A. Suh Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome Cell 119 2004 861
15. M.V. Blagosklonny, J. Toretsky, and S. Bohen Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90 Proc Natl Acad Sci USA 93 1996 8379
16. S.W. Lowe, H.E. Ruley, and T. Jacks p53-dependent apoptosis modulates the cytotoxicity of anticancer agents Cell 74 1996 957
17. U.K. Laemmli Cleavage of structural proteins during the assembly of the head of bacteriophage T4 Nature 227 1970 680
18. T. Mosmann Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays J Immunol Methods 65 1983 55
19. T.C. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 1984 27
20. J.N. Weinstein, T.G. Myers, and P.M. O'Connor An information-intensive approach to the molecular pharmacology of cancer Science 275 1997 343
21. J. Zha, H. Harada, and E. Yang Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L) Cell 87 1996 619
22. Y. Huang, P.E. Blower, and R. Liu Chemogenomic analysis identifies geldanamycins as substrates and inhibitors of ABCB1 Pharm Res 24 2007 1702
23. F. Teraishi, S. Wu, and J. Sasaki P-glycoprotein-independent apoptosis induction by a novel synthetic compound, MMPT [5-[(4-methylphenyl)methylene]-2- (phenylamino)-4(5H)-thiazolone] J Pharmacol Exp Ther 314 2005 355
24. T. Arumugam, V. Ramachandran, and K.F. Fournier Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer Cancer Res 69 2009 5820
25. S.M. Wilhelm, C. Carter, and L. Tang BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 2004 7099
26. M.V. Powers, and P. Workman Inhibitors of the heat shock response: Biology and pharmacology FEBS Lett 581 2007 3758